Next-generation sequencing (NGS) technology, which has been used at Illumina since 2007, builds upon earlier genome sequencing methods to greatly reduce the time taken to sequence DNA. When the ...

The IMCore of the UW Sensory Biology Center is pleased to announce the availability of an Illumina NextSeq 1000 sequencer. This equipment is purchased exclusively via an administrative supplement ...

The company forecast annual revenue of $4.28 billion to $4.4 billion for 2025, the midpoint of which is below analysts' ...

Element Biosciences’ bid to claim a slice of a DNA sequencing technology market dominated by Illumina has been helped by an impressive $277 million financing round backed by a wide range of ...

Q4 2024 Management View CEO Jacob Thaysen highlighted the transformative progress Illumina made in 2024, emphasizing its strategic roadmap targeting high single-digit revenue growth by 2027. He noted ...

Illumina shares tumbled 8% Friday on investor concerns about the future of the gene-sequencing equipment maker’s business in China, growing competitive threats, and the potential for Trump ...

San Diego gene sequencing giant Illumina is investing more in artificial intelligence to fuel the company’s growth strategy through a partnership with Nvidia. Nvidia — the Santa Clara tech ...

Work within a regulated sequencing workflow for developing diagnostic ... work in a research environment and use the full range of Illumina sequencing methods for a wide range of applications.

[1] Examples are platforms developed by companies such as Roche Applied Science (454 Genome Sequencer FLX [GS FLX] System; CT, USA), Illumina (Genome Analyzer [GA] II; CA, USA), Life Technologies ...

Illumina recently launched the MiSeq i100 and MiSeq i100 Plus Systems, two powerful, compact benchtop sequencers that incorporate more than 140 invention disclosures and 60 patent families.